1
|
Gallimore MJ, Friberger P. Prekallikrein Activator. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1661219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
| | - P Friberger
- KabiVitrum AB, Peptide Research, S-43133 Molndal, Sweden
| |
Collapse
|
2
|
Affiliation(s)
- D W Jones
- The Haemophilia Centre, Kent and Canterbury Hospitals NHS Trust, Ethelbert Road, Canterbury, Kent, UK
| | - M J Gallimore
- The Haemophilia Centre, Kent and Canterbury Hospitals NHS Trust, Ethelbert Road, Canterbury, Kent, UK
| | - M Winter
- The Haemophilia Centre, Kent and Canterbury Hospitals NHS Trust, Ethelbert Road, Canterbury, Kent, UK
| |
Collapse
|
3
|
Affiliation(s)
- M J Gallimore
- Abt. für Herz-, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| | - W Heller
- Abt. für Herz-, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| | - G Fuhrer
- Abt. für Herz-, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| | - H Wendel
- Abt. für Herz-, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| | - R Klaffschenkel
- Abt. für Herz-, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| | - H-E Hoffmeister
- Abt. für Herz-, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| |
Collapse
|
4
|
Affiliation(s)
- M J Gallimore
- Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| | - W Heller
- Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| | - G Fuhrer
- Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| | - H Wendel
- Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| | - R Klaffschenkel
- Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| | - H-E Hoffmeister
- Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany
| |
Collapse
|
5
|
Abstract
ZusammenfassungEinfache Untersuchungsmethoden für die Bestimmung der Spiegel des Plasma-Präkallikreins und anderer Komponenten der plasmatischen Abwehrsysteme sind jetzt verfügbar. Obwohl diese Tests bisher nicht voll in der Klinik verwendet wurden, so erhielt man doch eine Menge nützlicher Informationen mit Hilfe dieser Tests. Zahlreiche Laboratorien in Europa verwenden bereits diese Tests, um Patienten während Intensivbetreuung zu beobachten, und verwenden die Ergebnisse für die Entwicklung neuer Therapien. Weitere Zustände, in denen die Analyse der Komponenten dieser Systeme von Vorteil sein könnten, schließen die Organtransplantation, Lebererkrankungen, Nierenerkrankungen, die rheumatoide Arthritis, allergische Erkrankungen, Thrombosen, Hypertonie und koronare Herzerkrankung ein.
Collapse
|
6
|
Nicholls PJ, Donohoe S, Gallimore MJ, Winter M, Jones DW. Antibodies to Factor XII Are Distinct from Antibodies to Prothrombin in Patients with the Anti-phospholipid Syndrome. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1613021] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryPatients with the anti-phospholipid syndrome (APS) have antiphospholipid antibodies (aPA) which are often targeted towards phospholipid binding proteins such as β2-glycoprotein I and prothrombin. Antibodies to factor XII (FXIIabs) have also been identified in some patients with APS. Factor XII (FXII) is a member of the kringle family of proteins which include plasminogen and prothrombin. Antibodies to prothrombin have been associated with myocardial infarction and have been shown to cross react with plasminogen.Sixteen patients with APS and FXIIabs were investigated for the presence of antibodies to prothrombin, by enzyme linked immunosorbent assay in a calcium (Ca++) independent assay. All sixteen showed different antibody binding patterns than those observed for antibodies to FXII.Eight patients were further investigated using surface plasmon resonance (SPR) for antibody binding to covalently bound FXII and to covalently bound prothrombin in both Ca++ dependent and independent systems. Of three patients demonstrating antibody binding to FXII by SPR, none demonstrated antibody binding to prothrombin in a Ca++ independent system with one demonstrating antibody binding to prothrombin that was Ca++ dependent. Of five patients who did not bind FXII by SPR, one demonstrated antibody binding to prothrombin in a Ca++ independent system while two demonstrated antibody binding to prothrombin in a Ca++ dependent system. Antibodies to FXII in patients with APS appear to be distinct from antibodies to prothrombin.
Collapse
|
7
|
Abstract
SummaryFalsely low levels of factor XII (FXII) have been documented in patients who are lupus anticoagulant positive (LA+). In addition, we have previously noted a surprisingly high incidence (20.9%) of apparently true FXII deficiency in patients who were LA+. We have hypothesised that this may be partly due to the presence of antibodies to FXII.The aim of the present study was to investigate whether LA+ patient plasmas contain antibodies directed either against FXII or FXII in association with phospholipids. Plasma samples from 60 blood donors, all LA negative, and 51 LA+ patients were tested using ELISA assays employing purified FXII, phosphatidylserine (PS) and phosphatidylethanolamine (PE). We have identified seven patients whose plasma contained either IgG or IgM that reacted with purified FXII in the absence of PS or PE. When PS was included in the assay system four additional patient plasmas were shown to contain either IgG or IgM that reacted with FXII. The plasma of one patient contained IgG that reacted with FXII both in the presence and absence of PS. There was no reactivity to FXII with either IgG or IgM when PE was included in the assay system. Affinity purified IgG from three patients whose plasma reacted with FXII in the ELISA assay in the absence of PS, gave a positive reaction in an immunoblot assay. These results suggest that FXII antibodies are present in a significant proportion of LA+ patients and may lead to an erroneous diagnosis of FXII deficiency.
Collapse
|
8
|
Abstract
SummaryFactor XII (FXII) levels were determined in plasma samples from 29 normal donors, 10 patients with inherited FXII deficiency (all lupus anticoagulant [LA] negative) and 67 LA positive patients, using clotting (FXIIct), chromogenic substrate (FXIIcs) and immunochemical (FXIIag) assays. Excellent correlations were obtained in the three FXII assays with the LA negative samples and between the FXIIcs and FXIIag assays in the LA positive samples. Correlations between both the FXIIcs and FXIIag with FXIIct in the LA positive patients were poor. Of 67 LA positive samples studied, 25 (37.3%) showed lower values in the FXIIct assay; 13 (19.4%) of these patients were pseudo FXII deficient with values of FXII below the lower limit of normal.These results indicate that a diagnosis of FXII deficiency can be made inappropriately in the presence of phospholipid antibodies and that such a diagnosis should not be made by FXIIct assay alone.
Collapse
|
9
|
Tappenden KA, Gallimore MJ, Evans G, Mackie IJ, Jones DW. Thrombin generation in whole blood – response to Al Dieri & Hemker. Br J Haematol 2008. [DOI: 10.1111/j.1365-2141.2008.07110.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
|
11
|
Jones DW, Gallimore MJ, Winter M. More on: Pathogenic antibodies to coagulation factors. Part II: Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, protein C and von Willebrand factor. J Thromb Haemost 2006; 4:282-4. [PMID: 16409491 DOI: 10.1111/j.1538-7836.2005.01712.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Gallimore MJ, Harris SL, Tappenden KA, Winter M, Jones DW. Urokinase induced fibrinolysis in thromboelastography: a model for studying fibrinolysis and coagulation in whole blood. J Thromb Haemost 2005; 3:2506-13. [PMID: 16241949 DOI: 10.1111/j.1538-7836.2005.01615.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND The contact system (CS) proteins, factor XII and prekallikrein are thought to have roles in blood coagulation and fibrinolysis. Recent research has suggested that the CS proteins might be more important in fibrinolysis and cell function than in coagulation. Most studies on fibrinolysis have used plasma or euglobulin assays, ignoring the influence of cellular elements of blood on the fibrinolytic process. OBJECTIVE AND METHODS In order to study both coagulation and fibrinolysis in whole blood (WB), we have developed a thromboelastography (TEG) assay to investigate both coagulation and fibrinolysis in the same blood sample. In this assay, named urokinase (UK) induced fibrinolysis in thromboelastography (UKIFTEG), TEG is performed on recalcified citrated WB in the presence of UK. Large variations in Ly60 (percentage lysis 60 min after clot formation) were obtained between different donors with the same UK concentration. The UKIFTEG assay was therefore performed using UK concentrations that gave Ly60 values in the approximate range of 20-40%. RESULTS The effect of CS activation was investigated in the presence or absence of celite (10 mg mL(-1) blood). Celite shortened the clotting time (CT), and increased Ly60 values. Factor XIIa (FXIIa) and plasma kallikrein (KK) produced concentration dependent reductions in CT (significant at concentrations of 1303 and 2600 ng mL(-1) blood, respectively) and increased Ly60 values (significant at concentrations of 652 and 1300 ng mL(-1) blood, respectively). CONCLUSIONS Our results show that CS activation and both FXIIa and KK produce reductions in clotting time and enhanced fibrinolysis in UKIFTEG.
Collapse
Affiliation(s)
- M J Gallimore
- Kent Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, UK.
| | | | | | | | | |
Collapse
|
13
|
Harris SL, Jones DW, Gallimore MJ, Nicholls PJ, Winter M. The antigenic binding site(s) of antibodies to factor XII associated with the antiphospholipid syndrome. J Thromb Haemost 2005; 3:969-75. [PMID: 15869593 DOI: 10.1111/j.1538-7836.2005.01334.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Phospholipid binding proteins, including factor XII (FXII), are known to be targeted by antiphospholipid antibodies (aPA). Factor XII antibodies (FXIIab) have been described in some patients with the antiphospholipid syndrome (APS) and have been shown to lead to reduced levels of FXII. The antigenic binding site(s) and the pathophysiological effects of FXIIab are unknown. In an attempt to elucidate the binding site of these antibodies, immobilized plasma kallikrein was used to cleave FXII into its 52-kDa heavy-chain (HCFXII) and 28-kDa light-chain (LCFXII) components. Plasma samples from 12 female patients with definite APS and FXIIab were investigated for the presence of antibodies to FXII, HCFXII and LCFXII. All but one patient's plasma reacted to FXII, HCFXII and LCFXII in a similar manner. One patient gave markedly reduced positivity to HCFXII and LCFXII, suggesting that the FXIIab in this patient had a higher affinity for the intact FXII molecule. To further investigate the antigenic binding site(s) of FXII, 150 biotinylated peptides of the known FXII sequence were synthesized using a Multipin(TM) peptide synthesis procedure. The IgG and IgM fractions of the 12 patients' plasma were purified by affinity chromatography. The synthesized peptides were captured on streptavidin plates and individual patients' purified FXIIab assayed against the peptides in a modified enzyme-linked immunosorbent assay (ELISA). Two regions were identified as possible antigenic binding site(s) for FXIIab: one in the growth factor domain and the other in the catalytic domain.
Collapse
Affiliation(s)
- S L Harris
- Kent Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, UK.
| | | | | | | | | |
Collapse
|
14
|
Gallimore MJ, Jones DW, Winter M, Wendel HP. Changes in high molecular weight kininogen levels during and after cardiopulmonary bypass surgery measured using a chromogenic peptide substrate assay. Blood Coagul Fibrinolysis 2002; 13:561-8. [PMID: 12192309 DOI: 10.1097/00001721-200209000-00012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
High molecular weight kininogen (HK) is a co-factor in the blood-contact activation system. A chromogenic peptide substrate assay for HK (HKcs) has been developed in which test plasmas are mixed with diluted HK-deficient plasma and incubated with a soluble contact system activator that activates prekallikrein and factor XII. Calcium chloride, a synthetic thrombin inhibitor and a chromogenic peptide substrate for activated factor X (FXa) are then added. The FXa generated cleaves the FXa substrate releasing p-nitroanaline, which is measured photometrically. Test plasma HK values were calculated from a standard curve generated using a pooled normal plasma. Acceptable intra-assay and inter-assay precision values were obtained and levels of HK up to 200% were measurable. The assay measured HK in plasmas deficient in factor XII, prekallikrein and factor XI, was not affected by antiphospholipid antibodies and gave an acceptable correlation (r = 0.95) when normal plasmas and mixtures of HK-deficient and normal pooled plasma, calculated to give HK levels of 25 and 50%, were compared using HKcs and a HK one-stage clotting assay. The HKcs was used to measure HK levels in seven patients undergoing cardiopulmonary bypass (CPB). HK levels fell significantly during CPB (P = 0.0014) and were significantly higher (P = 0.016) 6 days after CPB, suggesting that HK may be a positive acute-phase reacting protein.
Collapse
Affiliation(s)
- M J Gallimore
- Kent Haemophilia Centre, Kent and Canterbury Hospital, UK.
| | | | | | | |
Collapse
|
15
|
Jone DW, Nicholls PJ, Donohoe S, Gallimore MJ, Winter M. Antibodies to factor XII are distinct from antibodies to prothrombin in patients with the anti-phospholipid syndrome. Thromb Haemost 2002; 87:426-30. [PMID: 11916074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
Patients with the anti-phospholipid syndrome (APS) have antiphospholipid antibodies (aPA) which are often targeted towards phospholipid binding proteins such as beta2-glycoprotein I and prothrombin. Antibodies to factor XII (FXIIabs) have also been identified in some patients with APS. Factor XII (FXII) is a member of the kringle family of proteins which include plasminogen and prothrombin. Antibodies to prothrombin have been associated with myocardial infarction and have been shown to cross react with plasminogen. Sixteen patients with APS and FXIIabs were investigated for the presence of antibodies to prothrombin, by enzyme linked immunosorbent assay in a calcium (Ca++) independent assay. All sixteen showed different antibody binding patterns than those observed for antibodies to FXII. Eight patients were further investigated using surface plasmon resonance (SPR) for antibody binding to covalently bound FXII and to covalently bound prothrombin in both Ca++ dependent and independent systems. Of three patients demonstrating antibody binding to FXII by SPR, none demonstrated antibody binding to prothrombin in a Ca++ independent system with one demonstrating antibody binding to prothrombin that was Ca++ dependent. Of five patients who did not bind FXII by SPR, one demonstrated antibody binding to prothrombin in a Ca++ independent system while two demonstrated antibody binding to prothrombin in a Ca++ dependent system. Antibodies to FXII in patients with APS appear to be distinct from antibodies to prothrombin.
Collapse
Affiliation(s)
- D W Jone
- Kent Haemophilia Centre, United Kingdom.
| | | | | | | | | |
Collapse
|
16
|
|
17
|
Scholz T, Solberg R, Okkenhaug C, Videm V, Gallimore MJ, Mathisen O, Pedersen T, Mollnes TE, Bergan A, Søreide O, Klintmalm GB, Aasen AO. Veno-venous bypass in liver transplantation: heparin-coated perfusion circuits reduce the activation of humoral defense systems in an in vitro model. Perfusion 2001; 16:285-92. [PMID: 11486847 DOI: 10.1177/026765910101600404] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
We studied the effects of bypass circuit surface heparinization on kallikrein-kinin, coagulation, fibrinolytic and complement activation in a closed model system for simulating veno-venous bypass (WBP) in orthotopic liver transplantation (OLT). The circuits were identical to those in routine use during clinical OLT in our institution. Fresh whole human blood diluted 1:2 with Ringer's acetate was circulated at a non-pulsatile flow (2 l/min) and at a constant temperature (37.5 degrees C) for 12 h. In 10 experiments, the entire inner surface of the circuits was coated with end-point attached heparin (HC). In the remaining 10, non-treated PVC tubing was used (NC). Components of the plasma kallikrein-kinin, coagulation, fibrinolytic and complement systems were analyzed using functional techniques (chromogenic peptide substrate assays) and enzyme immunoassays at baseline, 3 and 12 h. Significant activation of the initial (C3bc) and terminal (TCC) components of the complement system were found in both the NC and HC groups after 3 and 12 h: C3bc: NC: baseline = 4 (3.5-7.7), 3 h = 17.3* (12.5-27), 12h = 31* (17.7-63.6), HC: baseline = 4.9 (3.2-6.8), 3h = 9* (6-14.4), 12h = 13.7* (7.4-18.1). TCC: NC: baseline = 0.4 (0.2-0.6), 3h = 5*(0.8-11.9), 12 h: 13.1* (4.2-25.7). HC: baseline = 0.5 (0.1-0.6), 3 h = 0.6* (0.1-0.8), 12 h = 1.2* (0.3-2) AU/ml; median and range (*: p < 0.05). The C3bc and TCC concentrations were significantly higher in the NC group at 3 and 12 h, compared to the HC group: C3bc (NC vs. HC group): 3 h, p < 0.001; 12 h, p < 0.001. TCC (NC vs. HC group): 3h, p < 0.001; 12 h, p < 0.001. Significant increases in the values of thrombin-antithrombin complexes (p = 0.003), prothrombin fragment 1 + 2 (p = 0.006) and plasmin-alpha2-antiplasmin complexes (p = 0.016) were found in the non-coated group, but not in the heparin-coated group during the observation period, showing that the coagulation and fibrinolytic systems were activated in the non-coated circuits. We conclude that heparin-coating of the internal surface of the extracorporeal perfusion circuit used for WBP reduces activation of the plasma cascade systems in a closed venous system in vitro.
Collapse
Affiliation(s)
- T Scholz
- Institute for Surgical Research and Surgical Department, Rikshospitalet-National Hospital, Oslo, Norway
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
Forty female patients with either primary anti-phospholipid syndrome (n = 26) or systemic lupus erythematosus (anti-phospholipid syndrome positive) (n = 14) were investigated for levels of factor XII, the presence of lupus anticoagulant and antibodies to cardiolipin, beta 2-glycoprotein I and factor XII. Twenty-one patients had a history of recurrent fetal loss (> 2, mean = 2.6). Lupus anticoagulant positivity showed a weak association with recurrent fetal loss (odds ratio = 1.1). While there was no association between the presence of antibodies to cardiolipin or beta 2-glycoprotein I with recurrent fetal loss, antibodies to factor XII showed a strong and statistically significant association (odds ratio = 5.4, P = 0.025).
Collapse
Affiliation(s)
- D W Jones
- Kent Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, UK.
| | | | | | | |
Collapse
|
19
|
Cardigan RA, Mackie IJ, Gippner-Steppert C, Jochum M, Royston D, Gallimore MJ. Determination of plasma aprotinin levels by functional and immunologic assays. Blood Coagul Fibrinolysis 2001; 12:37-42. [PMID: 11229825 DOI: 10.1097/00001721-200101000-00006] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
We compared a functional (amidolytic) and an enzyme-linked immunosorbent assay (ELISA) method for determining aprotinin concentration in 82 plasma samples obtained from patients undergoing cardiac surgery with aprotinin therapy. There was good correlation between methods (r = 0.87); however, aprotinin measurements by chromogenic assay were significantly higher than by ELISA [234 +/- 104 kallikrein inhibitory units (KIU)/ml versus 155 +/- 88 KIU/ml; P = 0.0001]. This appeared to be attributable to differences in the potency of the material used to standardize the assays. When results were corrected to allow for potency of the standard, there was no significant difference between chromogenic and ELISA methods (234 +/- 104 KIU/ml versus 240 +/- 137 KIU/ ml), although the ELISA results tended to be higher in some samples. These data suggest that aprotinin concentrations measured by these methods cannot be used interchangeably, and care must be taken when interpreting data from studies measuring aprotinin.
Collapse
Affiliation(s)
- R A Cardigan
- Department of Haematology, University College London, UK.
| | | | | | | | | | | |
Collapse
|
20
|
Jones DW, Gallimore MJ, MacKie IJ, Harris SL, Winter M. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol 2000; 110:721-6. [PMID: 10997986 DOI: 10.1046/j.1365-2141.2000.02251.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Antibodies to factor XII (FXII) have previously been identified in some patients who were lupus anti-coagulant-positive. The relationship between these antibodies and FXII levels appeared to be variable. The aim of the present study was to confirm the presence of antibodies to FXII in patients with well characterized antiphospholipid syndrome (APS) and to establish their potential effect on levels of FXII. Forty-two patients with APS were studied; 21 patients were found to have either immunoglobulin (Ig)G or IgM antibodies to FXII by enzyme-linked immunosorbent assay (ELISA) using a highly purified preparation of FXII (> 99% pure). Levels of FXII were statistically significantly lower (P = 0.02) in patients with antibodies to FXII when compared with patients without antibodies to FXII (median = 91 micro/dl, s.d. = 39.1, median = 122 micro/dl, s.d. = 41.1 respectively). Four of the 21 patients with antibodies to FXII were found to have FXII levels below the laboratory normal range. Antibodies to FXII are present in significant numbers of patients with APS and may lead to acquired FXII deficiency.
Collapse
Affiliation(s)
- D W Jones
- Kent Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, United Kingdom.
| | | | | | | | | |
Collapse
|
21
|
Wendel HP, Jones DW, Gallimore MJ. FXII levels, FXIIa-like activities and kallikrein activities in normal subjects and patients undergoing cardiac surgery. Immunopharmacology 1999; 45:141-4. [PMID: 10615003 DOI: 10.1016/s0162-3109(99)00067-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A new chromogenic peptide substrate assay kit was used to measure factor XII (FXII) levels in plasma samples from 115 male patients with heart disease awaiting cardiac surgery, 40 age-matched normal healthy male blood donors and 20 patients before, during and after cardiopulmonary bypass surgery (CPB). Kallikrein-like and FXIIa-like activities were also determined in the CPB patient group. FXII levels were significantly lower (p = 0.0049) in the heart disease patients awaiting surgery when compared with values for the healthy donors and 13 patients (11.3%) had FXII levels below 50% compared with 1 normal donor (2.5%). During CPB significant decreases in FXII levels and significant increases in FXIIa-like and kallikrein-like activities were found indicating activation of the FXII-plasma kallikrein pathway during CPB.
Collapse
Affiliation(s)
- H P Wendel
- Department of Surgery, Eberhard-Karls-University, Tuebingen, Germany.
| | | | | |
Collapse
|
22
|
Scholz T, Gallimore MJ, Bäckman L, Mathisen O, Bergan A, Klintmalm GB, Aasen AO. Plasma proteolytic activity in liver transplant rejection. Transpl Int 1999; 12:100-7. [PMID: 10363591 DOI: 10.1007/s001470050193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In this study, we evaluated the role of proteolytic enzymes belonging to the coagulation, fibrinolytic, and plasma contact systems in the early postoperative phase after orthotopic liver transplantation (OLT). Twenty-nine patients were studied at the time of OLT and during the first 2 postoperative weeks. Blood samples were collected daily after OLT and analyzed for kallikrein-like activity (KK), functional kallikrein inhibition (KKI), plasmin-like activity (PL), and alpha2-antiplasmin (AP). In addition, prekallikrein (PKK), prothrombin (PTH), antithrombin III (AT III), plasminogen (PLG), prothrombin/antithrombin III complexes (TAT), prothrombin fragment 1 + 2 (F1 + 2), and plasmin/alpha2-antiplasmin complexes (PAP) were measured. Nineteen patients experienced biopsy-verified acute rejections (AR) and ten patients had uneventful courses and served as controls. Plasma analyses showed that the contact, coagulation, and fibrinolytic systems were activated during OLT. Following OLT, continuous thrombin and plasmin generation was observed, and these effects were more pronounced in the group having an uneventful course than in patients with AR. Factors that could possibly affect plasma proteolytic activity, such as blood product usage during and after OLT and cold ischemia time of the liver graft, did not differ between the groups, nor did the routine liver function tests, alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
Collapse
Affiliation(s)
- T Scholz
- Institute for Surgical Research and Surgical Department B, Rikshospitalet, The National Hospital, Oslo, Norway
| | | | | | | | | | | | | |
Collapse
|
23
|
Gallimore MJ, Jones DW, Wendel HP. A chromogenic substrate assay kit for factor XII: evaluation and use for the measurement of factor XII levels in cardiopulmonary bypass patients. Thromb Res 1999; 94:103-9. [PMID: 10230895 DOI: 10.1016/s0049-3848(98)00202-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Factor XII levels were determined in plasma samples from 75 patients before undergoing aortocoronary bypass grafting and from 40 healthy age-matched donors by using a microtitre plate adaptation of a new chromogenic peptide substrate assay kit for factor XII. The chromogenic peptide substrate assay values for factor XII correlated well with those obtained in clotting (r=0.90; y= 15.811+0.8236x) and immunochemical (r=0.88; y=17.90+0.817x) assays in the normal donor samples. Factor XII levels in the patients were significantly lower than those in the normal donors (83.3+/-23.2% versus 103.4+/-23.1: p=0.004), and nine patients (12%) had factor XII values below 50% compared with only one of the normal donors (2.5%). Factor XII levels and kallikrein-like activities (a measure of contact system activation) were followed before, during, and one day after cardiopulmonary bypass in 20 patients. Factor XII levels were significantly reduced, and kallikrein-like activities significantly elevated after 5 and 30 minutes cardiopulmonary bypass. One day after cardiopulmonary bypass both factor XII levels and kallikrein-like activities were significantly lower than preoperation values.
Collapse
Affiliation(s)
- M J Gallimore
- Kent Haemophilia Centre, Kent and Canterbury Hospital, United Kingdom
| | | | | |
Collapse
|
24
|
Jones DW, Gallimore MJ, Harris SL, Winter M. Antibodies to factor XII associated with lupus anticoagulant. Thromb Haemost 1999; 81:387-90. [PMID: 10102466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Falsely low levels of factor XII (FXII) have been documented in patients who are lupus anticoagulant positive (LA+). In addition, we have previously noted a surprisingly high incidence (20.9%) of apparently true FXII deficiency in patients who were LA+. We have hypothesised that this may be partly due to the presence of antibodies to FXII. The aim of the present study was to investigate whether LA+ patient plasmas contain antibodies directed either against FXII or FXII in association with phospholipids. Plasma samples from 60 blood donors, all LA negative, and 51 LA+ patients were tested using ELISA assays employing purified FXII, phosphatidylserine (PS) and phosphatidylethanolamine (PE). We have identified seven patients whose plasma contained either IgG or IgM that reacted with purified FXII in the absence of PS or PE. When PS was included in the assay system four additional patient plasmas were shown to contain either IgG or IgM that reacted with FXII. The plasma of one patient contained IgG that reacted with FXII both in the presence and absence of PS. There was no reactivity to FXII with either IgG or IgM when PE was included in the assay system. Affinity purified IgG from three patients whose plasma reacted with FXII in the ELISA assay in the absence of PS, gave a positive reaction in an immunoblot assay. These results suggest that FXII antibodies are present in a significant proportion of LA+ patients and may lead to an erroneous diagnosis of FXII deficiency.
Collapse
Affiliation(s)
- D W Jones
- Kent Haemophilia Centre, Canterbury Hospitals NHS Trust, United Kingdom.
| | | | | | | |
Collapse
|
25
|
|
26
|
Abstract
We have developed an automated chromogenic peptide substrate assay for factor XII (FXIIcs) on a Cobas Mira S Plus clinical chemistry analyser using a new commercially available kit. This was used to determine factor XII (FXII) levels in plasma samples from 320 blood donors, 206 patients with a history of venous thrombosis and 74 lupus anticoagulant positive (LA+) patients. Results were compared with those obtained in a clotting assay for FXII (FXIIct) and an immunochemical assay (FXIIag). A satisfactory correlation coefficient of 0.92 and a regression line equation of y = 7.898 + 0.871x was obtained between FXIIcs and FXIIct in the 320 blood donors. Levels of FXII below the calculated normal range were found in nine blood donors (2.8%) and 16 venous thrombosis patients (7.8%). The blood donors and patients with venous thrombosis with low FXIIcs values had FXII levels below our lower limits of normal for both FXIIct and FXIIag; all were lupus anticoagulant negative. When FXII levels were determined in the 74 LA+ patients, 27 (36.5%) gave markedly lower FXII values in the FXIIct when compared with the FXIIcs. FXIIag levels corresponded with FXIIcs. The automated FXIIcs assay is therefore lupus anticoagulant insensitive and allows us to measure FXII levels accurately and routinely in large numbers of patient samples.
Collapse
Affiliation(s)
- D W Jones
- Haemophilia Comprehensive Care Centre, Kent and Canterbury Hospitals NHS Trust, Canterbury, Kent, UK.
| | | | | |
Collapse
|
27
|
Gallimore MJ, Jones DW, Winter M. Factor XII determinations in the presence and absence of phospholipid antibodies. Thromb Haemost 1998; 79:87-90. [PMID: 9459329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Factor XII (FXII) levels were determined in plasma samples from 29 normal donors, 10 patients with inherited FXII deficiency (all lupus anticoagulant [LA] negative) and 67 LA positive patients, using clotting (FXIIct), chromogenic substrate (FXIIcs) and immunochemical (FXIIag) assays. Excellent correlations were obtained in the three FXII assays with the LA negative samples and between the FXIIcs and FXIIag assays in the LA positive samples. Correlations between both the FXIIcs and FXIIag with FXIIct in the LA positive patients were poor. Of 67 LA positive samples studied, 25 (37.3%) showed lower values in the FXIIct assay; 13 (19.4%) of these patients were pseudo FXII deficient with values of FXII below the lower limit of normal. These results indicate that a diagnosis of FXII deficiency can be made inappropriately in the presence of phospholipid antibodies and that such a diagnosis should not be made by FXIIct assay alone.
Collapse
Affiliation(s)
- M J Gallimore
- Haemophilia Centre, Kent and Canterbury Hospitals NHS Trust, United Kingdom
| | | | | |
Collapse
|
28
|
Jones DW, Gallimore MJ, Winter M. Factor XII determinations and lupus anticoagulants. Blood Coagul Fibrinolysis 1997; 8:531-2. [PMID: 9491272 DOI: 10.1097/00001721-199711000-00008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
29
|
Wendel HP, Heller W, Gallimore MJ. Heparin-coated devices and high-dose aprotinin optimally inhibit contact system activation in an in vitro cardiopulmonary bypass model. Immunopharmacology 1996; 32:128-30. [PMID: 8796289 DOI: 10.1016/0162-3109(95)00073-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- H P Wendel
- Department of Thoracic and Cardiovascular Surgery, University of Tuebingen, Germany
| | | | | |
Collapse
|
30
|
Wendel HP, Heller W, Gallimore MJ. Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model. Immunopharmacology 1996; 32:57-61. [PMID: 8796267 DOI: 10.1016/0162-3109(96)00009-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
In the present study we used an in vitro cardiopulmonary bypass model to compare activation of the FXII-plasma kallikrein systems, coagulation pathway and blood cell changes, with heparin (3 U/ml), heparin plus aprotinin (3 U/ml and 250 KIU/ml) and recombinant hirudin (6 micrograms/ml). After 90 min circulation the results showed that with heparin plus aprotinin and with hirudin the activation of these cascade reactions was markedly lower. In particular kallikrein-like activities and PMN-Elastase-alpha 1-PI levels were significantly lower in the latter two groups. The least activation was detected with hirudin. Our results confirm that the contact systems of blood are activated during CPB with heparin as anticoagulant, that aprotinin reduces this activation, and that recombinant hirudin may be preferred to heparin as an anticoagulant in cardiac surgery.
Collapse
Affiliation(s)
- H P Wendel
- Department of Thoracic and Cardiovascular Surgery, University of Tuebingen, Germany
| | | | | |
Collapse
|
31
|
Jones DW, Gallimore MJ, Winter M. Pseudo factor XII deficiency and phospholipid antibodies. Thromb Haemost 1996; 75:696-7. [PMID: 8743205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|
32
|
Jones DW, Winter M, Gallimore MJ. P37. Phospholipid antibodies may affect coagulation assays for factor XII. Blood Coagul Fibrinolysis 1996. [DOI: 10.1097/00001721-199604000-00096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Wendel HP, Heller W, Gallimore MJ, Hoffmeister HE. Heparin-coated oxygenators significantly reduce contact system activation in an in vitro cardiopulmonary bypass model. Blood Coagul Fibrinolysis 1994; 5:673-8. [PMID: 7865672 DOI: 10.1097/00001721-199410000-00001] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Over the past decade our group has shown that the contact system of blood is activated in cardiopulmonary bypass (CPB), that heparins enhance this activation and that aprotinin reduces both this activation and blood loss in CPB. We have developed an in vitro CPB model to assess the effects of added components to blood and new components in the artificial devices of CPB. In the present study we have compared membrane oxygenators with or without heparin-coated surfaces under identical conditions in the CPB model. Recalcified ACD blood was circulated in a closed system for 90 min at 28 degrees C. Blood samples were taken at various times during circulation. 4 IU/ml heparin was used with the non-coated oxygenators; no heparin was used in the coated system. Heparin levels were measured in the plasma together with various contact system components. Haemolysis, platelet count, platelet factor 4 and alpha 1-proteinase inhibitor-PMN elastase complexes, were also determined. No heparin was detected during the period of recirculation in samples from the coated oxygenators, showing the excellent adhesive quality of the heparin coating. In keeping with a significant greater fall in the platelet count in non-coated vs coated oxygenators (mean [+/- SD] final counts of 170 +/- 50 x 10(9)/l and 97 +/- 34.2 x 10(9)/l respectively after 90 min circulation), platelet factor 4 levels were significantly higher (682.9 +/- 187.3% and 95.8 +/- 46.5% of the initial value respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- H P Wendel
- Department of Thoracic and Cardiovascular Surgery, University of Tübingen, Germany
| | | | | | | |
Collapse
|
34
|
Affiliation(s)
- H P Wendel
- Department of Thoracic and Cardiovascular Surgery, University of Tübingen, Germany
| | | | | |
Collapse
|
35
|
Wendel HP, Heller W, Gallimore MJ, Bantel H, Müller-Beissenhirtz H, Hoffmeister HE. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis 1993; 4:41-5. [PMID: 7681331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In cardiopulmonary bypass (CPB) surgery high dose heparin is necessary to inhibit the clotting cascade which is activated through damage to the vessels (extrinsic pathway) as well as contact activation of the blood with the various artificial surfaces of the CPB machine (intrinsic pathway). In most European heart surgery centres, the fibrinolytic activation that always occurs in CPB due to contact activation is reduced by the proteinase inhibitor aprotinin. Monitoring of anticoagulation during CPB is performed with the activated whole blood clotting time (ACT). The two machines commonly used for this purpose, Hemotec and Hemochron, use different contact system activators, kaolin and celite. These activators displayed highly significant differences, in both in vitro tests (modified APTT with whole blood in a neutral coagulometer), and ACT in both machines where aprotinin and heparin were used, as well as with parallel measurements with the two machines with blood from patients undergoing CPB with high dose aprotinin therapy (P < 0.001). The Hemotec machine with kaolin as activator was not affected by aprotinin throughout surgery, while the Hemochron clotting times almost doubled as soon as aprotinin and heparin were combined. Our studies show that for the determination of ACT in CPB were high dose aprotinin therapy is used only ACT determinations with machines using kaolin as activator yield accurate results.
Collapse
Affiliation(s)
- H P Wendel
- Department of Thoracic, Heart and Vascular Surgery, University of Tübingen, Germany
| | | | | | | | | | | |
Collapse
|
36
|
Gallimore MJ, Heller W, Fuhrer G, Wendel H, Klaffschenkel R, Hoffmeister HE. Contact activation, heparins and cardiopulmonary bypass. Thromb Haemost 1993; 69:92-3. [PMID: 8446948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
37
|
Gallimore MJ, Heller W, Fuhrer G, Wendel H, Klaffschenkel R, Hoffmeister HE. Contact activation, heparins and cardiopulmonary bypass. Thromb Haemost 1992; 68:91-4. [PMID: 1514183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
38
|
Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass--effects on the Hageman factor (FXII)--Kallikrein system and blood loss. Blood Coagul Fibrinolysis 1992; 3:99-104. [PMID: 1377956 DOI: 10.1097/00001721-199202000-00014] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Aprotinin has been used in our hospital in open heart surgery for almost 20 years and recently published studies have revealed a reduction in postoperative blood loss under this therapy. In the present study patients undergoing aorto-coronary bypass operations received either 20,000 KIU aprotinin/kg body weight (group 2) or 60,000 KIU aprotinin/kg body weight (group 3). Another group of patients without aprotinin served as a control (group 1) and postoperative bleeding was more pronounced in these patients compared with the other groups. In parallel, slight reductions in kallikrein-like activity were observed in patients treated with aprotinin. Furthermore, we have shown that the main inhibitor of the contact phase, C1-esterase-inhibitor, loses some of its activity against beta-FXIIa in the presence of heparin. Aprotinin was able to partly antagonize this phenomenon. All studies dealing with the effect of aprotinin in extracorporeal circulation demonstrate hyperfibrinolysis in untreated patients. Aprotinin is known to inhibit plasmin at low concentrations and thus reduced the postoperative bleeding tendency (group 2). In addition, plasma kallikrein is inhibited by high aprotinin concentrations and is responsible for a reduced activation of the contact phase system. This effect led to a further reduction in blood loss (group 3).
Collapse
Affiliation(s)
- G Fuhrer
- Chir. Klinik, Kreiskrankenhaus Reutlingen, Germany
| | | | | | | |
Collapse
|
39
|
Abstract
Chromogenic peptide substrates were first introduced into research laboratories in the early 1970s and were quickly utilised to develop assays for the determination of enzymes, proenzymes and inhibitors of the coagulation system. These assays were gradually introduced into coagulation and clinical chemistry laboratories as laboratory tools in the diagnosis and treatment of coagulation disorders. From the knowledge of the structures of the natural substrates attacked by enzymes other than those of the coagulation system or by synthesis and random screening, substrates for enzymes of the fibrinolytic, plasma and glandular kallikrein and complement systems were produced. These allowed various research groups to develop assays for components of these systems and subsequently led to the use of these assays in studies on various clinical conditions. Substrates for activated protein C ensured that assays for this enzyme and its inhibitors could be developed and introduced into the haematological routine. With the introduction of substrates for limulus lysate not only were assays for endotoxins in clinical samples produced but the control of all disposable products and injectables for endotoxin contamination can now be effected. Initially high costs and time-consuming manual assays were a hinderence to the general acceptance of the use of chromogenic peptide substrate assays and they were only used routinely in a few specialised laboratories. With the introduction of automated and microtitre plate methods however, these assays are are now available in most hospital laboratories. Since the first chromogenic peptide substrate was described thousands of articles have been published on the use of chromogenic substrate assays to measure proenzymes, enzyme activators, enzyme cofactors and inhibitors in blood and other body fluids in normal subjects and clinical material. We have endeavoured to cover as many of these as possible in this review.
Collapse
|
40
|
Abstract
The plasma protein FXII (Hageman factor) has been shown to be linked with the plasma defence systems of coagulation, fibrinolysis, kallikrein-kinin and complement. It can be activated by surface contact activation and in solution. Surface contact activation is a complex phenomenon involving negatively charged surfaces, FXII, high molecular weight kininogen and plasma kallikrein. Fluid-phase activation can be effected by a variety of serine proteases. In both types of activation the FXII zymogen is converted to active enzymes. FXII levels in plasma are low or undetectable in both inherited deficiencies and in a variety of clinical conditions. FXII levels can also be elevated in some clinical conditions. Although discovered as a clotting protein FXII appears to play an important role in the kallikrein-kinin and fibrinolytic systems and also has effects on cells. Recent studies suggest that therapeutic blockade of activation of FXII can be of benefit in certain clinical conditions.
Collapse
Affiliation(s)
- G Fuhrer
- Kreiskrankenhaus Reutlingen, Federal Republic of Germany
| | | | | | | |
Collapse
|
41
|
Grand RJ, Grabham PW, Gallimore MJ, Gallimore PH. Modulation of morphological differentiation of human neuroepithelial cells by serine proteases: independence from blood coagulation. EMBO J 1989; 8:2209-15. [PMID: 2792085 PMCID: PMC401150 DOI: 10.1002/j.1460-2075.1989.tb08344.x] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
We have previously shown that a serum protein, termed differentiation reversal factor (DRF), is responsible for neurite retraction in differentiated cultures of an adenovirus 12 (Ad12) transformed human retinoblast cell line. Data is presented here to show that DRF is identical to the serine protease prothrombin. Both proteins have been immunoprecipitated using an antibody raised against purified prothrombin and have been shown to hydrolyse a specific thrombin substrate only after activation by the snake venom ecarin. Following addition to Ad12 HER 10 cells, which had previously been differentiated by culture in the presence of 2 mM dibutyryl cAMP in serum-free medium, thrombin and prothrombin caused half-maximal retraction of neurites at concentrations of 0.5 ng/ml and 20 ng/ml respectively. Interestingly, activation of prothrombin was shown to be unnecessary for biological activity. Using the inhibitor di-isopropylfluorophosphate (DIP), we have shown that abrogation of the proteolytic activity of thrombin also results in a loss (greater than 2000 fold) of differentiation reversal activity. Thrombin and its zymogen both stimulated the mitosis of differentiated Ad12 HER 10 cells to a similar extent. In addition, differentiation reversal was highly specific since, at physiologically significant concentrations, closely related serine proteases did not cause neurite retraction. Prothrombin and thrombin also reversed morphological differentiation in the SK-N-SH neuroblastoma cell line and in heterogeneous cultures of cells from various regions in the human foetal brain.
Collapse
Affiliation(s)
- R J Grand
- Department of Cancer Studies, University of Birmingham, Medical School, Walmer, Kent, UK
| | | | | | | |
Collapse
|
42
|
Gallimore MJ, Fuhrer G, Heller W, Hoffmeister HE. Augmentation of kallikrein and plasmin inhibition capacity by aprotinin using a new assay to monitor therapy. Adv Exp Med Biol 1989; 247B:55-60. [PMID: 2481953 DOI: 10.1007/978-1-4615-9546-5_9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- M J Gallimore
- Dept. of Cardiovascular Surgery, University of Tuebingen, FRG
| | | | | | | |
Collapse
|
43
|
Heller W, Fuhrer G, Gallimore MJ, Michel J, Hoffmeister HE. Changes in the kallikrein-kinin-system after different dose regimen of aprotinin during cardiopulmonary bypass operation. Adv Exp Med Biol 1989; 247B:43-8. [PMID: 2481948 DOI: 10.1007/978-1-4615-9546-5_7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- W Heller
- Department of Cardiovascular Surgery, University of Tübingen, FRG
| | | | | | | | | |
Collapse
|
44
|
Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Studies on the inhibition of plasma kallikrein, C1-esterase and beta-FXIIa in the presence and the absence of heparins. Adv Exp Med Biol 1989; 247B:61-6. [PMID: 2610099 DOI: 10.1007/978-1-4615-9546-5_10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- G Fuhrer
- Department of Cardiovascular Surgery, University of Tübingen, FRG
| | | | | | | |
Collapse
|
45
|
Fuhrer G, Gallimore MJ, Lambrecht M, Heller W. Factor XII levels in patients after abdominal surgery. Adv Exp Med Biol 1989; 247B:509-14. [PMID: 2610089 DOI: 10.1007/978-1-4615-9546-5_84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- G Fuhrer
- Department of Cardiovascular Surgery, University of Tuebingen, FRG
| | | | | | | |
Collapse
|
46
|
Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Changes in components of the KK-system after recirculation and the addition of plasma kallikrein. Adv Exp Med Biol 1989; 247A:481-6. [PMID: 2603814 DOI: 10.1007/978-1-4615-9543-4_74] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- G Fuhrer
- Department of Cardiovascular Surgery, University of Tübingen, FRG
| | | | | | | |
Collapse
|
47
|
Schrader J, Gallimore MJ, Eisenhauer T, Isemer FE, Schoel G, Warneke G, Brüggemann M, Scheler F. Parameters of the kallikrein-kinin, coagulation and fibrinolytic systems as early indicators of kidney transplant rejection. Nephron Clin Pract 1988; 48:183-9. [PMID: 3281044 DOI: 10.1159/000184909] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
In order to find early indicators of kidney transplant rejection before clinical symptoms were noticed, parameters of the coagulation, fibrinolytic and kallikrein-kinin systems were measured. Nineteen patients were followed before and daily after kidney transplantation during the first week and every second day in the following weeks. All patients received immunosuppressive therapy with cyclosporin and corticoids. Ten patients suffered from transplant rejection. The first rejection occurred on the 7th day after transplantation. Of all the parameters measured, kallikrein inhibition, beta-FXIIa inhibition, plasminogen and antithrombin III were early indicators of kidney transplant rejections. A rise in these parameters could be demonstrated 2-3 days before clinical signs were noticed. In the other 9 patients no significant rises in antithrombin III, plasminogen, kallikrein inhibition and beta-FXIIa inhibition could be found.
Collapse
|
48
|
Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass. Adv Exp Med Biol 1986; 198 Pt B:385-91. [PMID: 2433915 DOI: 10.1007/978-1-4757-0154-8_49] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
49
|
Abstract
Screening of chromogenic peptide substrates have shown that FXIIa readily splits substrates of D-Pro-Phe-Arg-pNA (S-2302) and -Gly-Arg-pNA (e.g. S-2222) types. The latter type is preferred in a system where kallikrein is present. By using the substrate S-2222 a method for the determination of beta FXIIa inhibitors has been designed. Chromatography data show that C1-esterase inhibitor is the major inhibitor of beta FXIIa in plasma. Preliminary studies have also been performed on the assay of FXII in human plasma. The procedure to obtain a complete activation of FXII has still to be studied.
Collapse
|
50
|
Friberger P, Gallimore MJ. Description and evaluation of a new chromogenic substrate assay kit for the determination of prekallikrein in human plasma. Adv Exp Med Biol 1986; 198 Pt B:543-8. [PMID: 3643742 DOI: 10.1007/978-1-4757-0154-8_69] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Because of an increasing interest in the determination of prekallikrein a kit was made for the determination of this plasma proenzyme. The kit consists of 1) a prekallikrein activator of the cephalin-ellagic acid type containing Factor XII and HMW-kininogen to ensure a total activation of the prekallikrein even in pathological plasmas, 2) a buffer which is optimal for both activation and substrate hydrolysis and 3) the chromogenic substrate S-2302. A control plasma is also included. This kit was evaluated by thirteen research groups as well as by ourselves. Both normal and patient plasmas were analyzed. Good correlations were obtained for prekallikrein levels in plasma samples between the kit method and two other methods (immunochemical and functional). As well as in deficiency states the prekallikrein level was low in pancreatitis (n = 20), cancer (n = 16), early pregnancy with gestosis (n = 15), cirrhosis (n = 9) and cases with thromboembolic disorders (n = 5). The prekallikrein level was high in late pregnancy (n = 4).
Collapse
|